This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Should Investors Buy Bristol Myers Squibb Stock?
by Shaun Pruitt
BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
by Zacks Equity Research
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.
Bristol Myers Squibb (BMY) Stock Moves -0.86%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.09, marking a -0.86% move from the previous day.
Bristol Myers Squibb (BMY) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.71, marking a -0.49% move from the previous day.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
by Zacks Equity Research
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from the previous trading session.
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
by Zacks Equity Research
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval
by Zacks Equity Research
Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.
Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
Bristol Myers Squibb (BMY) Stock Moves -0.36%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $71.52 in the latest trading session, marking a -0.36% move from the prior day.
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.47, marking a -0.8% move from the previous day.
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
Company News for Sep 13, 2022
by Zacks Equity Research
Companies in The News Are: AAPL, BMY, TWTR, GILD
Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $69.38 in the latest trading session, marking a +0.9% move from the prior day.
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
by Zacks Equity Research
Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.
Bristol Myers Squibb (BMY) Stock Moves -0.69%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $68.61 in the latest trading session, marking a -0.69% move from the prior day.
Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News
by Zacks Equity Research
Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.
Bristol Myers (BMY) Announces Milvexian Phase II Study Results
by Zacks Equity Research
Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.